Uni Eropa - Spanyol - EMA (European Medicines Agency)

acino ag - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - agentes antitrombóticos - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.

Uni Eropa - Spanyol - EMA (European Medicines Agency)

viiv healthcare bv - la lamivudina, zidovudina - infecciones por vih - antivirales para uso sistémico - combivir is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection.

Uni Eropa - Spanyol - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - daclatasvir dihidrocloruro - hepatitis c, crónica - antivirales para uso sistémico - daklinza está indicado en combinación con otros medicamentos para el tratamiento de la infección crónica por el virus de la hepatitis c (vhc) en adultos (ver secciones 4. 2, 4. 4 y 5. para el vhc de genotipo actividad específica, consulte las secciones 4. 4 y 5.

Uni Eropa - Spanyol - EMA (European Medicines Agency)

janssen-cilag international n.v. - daratumumab - mieloma múltiple - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. en combinación con bortezomib, la talidomida y dexametasona para el tratamiento de pacientes adultos con diagnóstico reciente de mieloma múltiple, que son elegibles para el trasplante autólogo de células madre. en combinación con lenalidomida y dexametasona, o bortezomib y dexametasona para el tratamiento de pacientes adultos con mieloma múltiple que han recibido al menos una terapia previa. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. como monoterapia para el tratamiento de pacientes adultos con recaída y refractarios mieloma múltiple, cuya antes de la terapia incluye un inhibidor del proteasoma y un agente inmunomodulador y que han demostrado que la progresión de la enfermedad en la última terapia. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.

Uni Eropa - Spanyol - EMA (European Medicines Agency)

gilead sciences ireland uc - emtricitabina, tenofovir alafenamide - infecciones por vih - antivirales para uso sistémico - descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (hiv-1).

Uni Eropa - Spanyol - EMA (European Medicines Agency)

shire pharmaceutical contracts limited - epoetina delta - kidney failure, chronic; anemia - preparaciones antianémicas - dynepo está indicado para el tratamiento de la anemia sintomática asociada a la insuficiencia renal crónica (irc) en pacientes adultos. se puede usar en pacientes en diálisis y en pacientes que no reciben diálisis.

Uni Eropa - Spanyol - EMA (European Medicines Agency)

mylan pharmaceuticals limited - emtricitabina, tenofovir disoproxil maleato de - infecciones por vih - antivirales para uso sistémico - treatment of hiv-1 infection:emtricitabine/tenofovir disoproxil mylan is indicated in antiretroviral combination therapy for the treatment of hiv-1 infected adults (see section 5. emtricitabine/tenofovir disoproxil mylan is also indicated for the treatment of hiv-1 infected adolescents, with nrti resistance or toxicities precluding the use of first line agents, (see sections 4. 2, 4. 4 y 5. pre-exposure prophylaxis (prep):emtricitabine/tenofovir disoproxil mylan is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired hiv-1 infection in adults and adolescents at high risk (see sections 4. 2, 4. 4 y 5.

Uni Eropa - Spanyol - EMA (European Medicines Agency)

gilead sciences ireland uc - sofosbuvir, velpatasvir - hepatitis c, crónica - antivirales para uso sistémico - epclusa is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients 3 years of age and older (see sections 4. 2, 4. 4 y 5.

Uni Eropa - Spanyol - EMA (European Medicines Agency)

viiv healthcare bv - lamivudina - infecciones por vih - antivirales para uso sistémico - epivir está indicado como parte de la terapia de combinación antirretroviral para el tratamiento de adultos y niños infectados por el virus de la inmunodeficiencia humana (vih).

Uni Eropa - Spanyol - EMA (European Medicines Agency)

ratiopharm gmbh - epoetina theta - kidney failure, chronic; anemia; cancer - otros antianémico preparaciones - tratamiento de la anemia sintomática asociada a la insuficiencia renal crónica en pacientes adultos. tratamiento de la anemia sintomática en pacientes adultos con cáncer no mieloides malignas que reciben quimioterapia.